No Association between PIK3CA Polymorphism and Lung Cancer Risk in the Korean Population.
('No', 'No', 'DT', 'B-NP', 'O')
('Association', 'Association', 'NN', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'B-NP', 'B-DNA')
('Polymorphism', 'Polymorphism', 'NN', 'I-NP', 'I-DNA')
('and', 'and', 'CC', 'O', 'O')
('Lung', 'Lung', 'NNP', 'B-NP', 'O')
('Cancer', 'Cancer', 'NNP', 'I-NP', 'O')
('Risk', 'Risk', 'NNP', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Korean', 'Korean', 'NNP', 'I-NP', 'O')
('Population.', 'Population.', 'NNP', 'I-NP', 'O')
The PIK3CA gene, oncogenic gene located on human chromosome 3q26.3, is an important regulator of cell proliferation, death, motility and invasion.
('The', 'The', 'DT', 'B-NP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'I-NP', 'B-DNA')
('gene,', 'gene,', 'NN', 'I-NP', 'I-DNA')
('oncogenic', 'oncogenic', 'JJ', 'I-NP', 'I-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('located', 'locate', 'VBN', 'B-VP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('human', 'human', 'JJ', 'B-NP', 'B-DNA')
('chromosome', 'chromosome', 'NN', 'I-NP', 'I-DNA')
('3q26.3,', '3q26.3,', 'NN', 'I-NP', 'I-DNA')
('is', 'be', 'VBZ', 'B-VP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('important', 'important', 'JJ', 'I-NP', 'O')
('regulator', 'regulator', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('cell', 'cell', 'NN', 'B-NP', 'O')
('proliferation,', 'proliferation,', 'NN', 'I-NP', 'O')
('death,', 'death,', 'NN', 'I-NP', 'O')
('motility', 'motility', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('invasion.', 'invasion.', 'NN', 'B-NP', 'O')
To evaluate the role of PIK3CA gene in the risk of Korean lung cancer, genotypes of the PIK3CA polymorphisms (rs11709323, rs2699895, rs3729679, rs17849074 and rs1356413) were determined in 423 lung cancer patients and 443 normal controls.
('To', 'To', 'TO', 'B-VP', 'O')
('evaluate', 'evaluate', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('role', 'role', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'B-NP', 'B-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('risk', 'risk', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('Korean', 'Korean', 'JJ', 'B-NP', 'O')
('lung', 'lung', 'NN', 'I-NP', 'O')
('cancer,', 'cancer,', 'NN', 'I-NP', 'O')
('genotypes', 'genotype', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'I-NP', 'B-DNA')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'I-DNA')
('(rs11709323,', '(rs11709323,', 'VBD', 'B-VP', 'O')
('rs2699895,', 'rs2699895,', 'NN', 'B-NP', 'O')
('rs3729679,', 'rs3729679,', 'NN', 'I-NP', 'O')
('rs17849074', 'rs17849074', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('rs1356413)', 'rs1356413)', 'NN', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('determined', 'determine', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('423', '423', 'CD', 'B-NP', 'O')
('lung', 'lung', 'NN', 'I-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('443', '443', 'CD', 'B-NP', 'O')
('normal', 'normal', 'JJ', 'I-NP', 'O')
('controls.', 'controls.', 'NNS', 'I-NP', 'O')
Statistical analyses revealed that the genotypes and haplotypes in the PIK3CA gene were not significantly associated with the risk of lung cancer in the Korean population, suggesting that these PIK3CA polymorphisms do not contribute to the genetic susceptibility to lung cancer in the Korean population.
('Statistical', 'Statistical', 'JJ', 'B-NP', 'O')
('analyses', 'analysis', 'NNS', 'I-NP', 'O')
('revealed', 'reveal', 'VBD', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('genotypes', 'genotype', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('haplotypes', 'haplotype', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'I-NP', 'B-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('were', 'be', 'VBD', 'B-VP', 'O')
('not', 'not', 'RB', 'I-VP', 'O')
('significantly', 'significantly', 'RB', 'I-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('risk', 'risk', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Korean', 'Korean', 'JJ', 'I-NP', 'O')
('population,', 'population,', 'NN', 'I-NP', 'O')
('suggesting', 'suggest', 'VBG', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('these', 'these', 'DT', 'B-NP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'I-NP', 'B-DNA')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'I-DNA')
('do', 'do', 'VBP', 'B-VP', 'O')
('not', 'not', 'RB', 'I-VP', 'O')
('contribute', 'contribute', 'VB', 'I-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('genetic', 'genetic', 'JJ', 'I-NP', 'O')
('susceptibility', 'susceptibility', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Korean', 'Korean', 'JJ', 'I-NP', 'O')
('population.', 'population.', 'NN', 'I-NP', 'O')
Lung cancer has been the leading cause of cancerrelated deaths in Korea, and its incidence continues to rise (Shin et al., 2007).
('Lung', 'Lung', 'NN', 'B-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('has', 'have', 'VBZ', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('leading', 'lead', 'VBG', 'I-NP', 'O')
('cause', 'cause', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('cancerrelated', 'cancerrelate', 'VBN', 'B-NP', 'O')
('deaths', 'death', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Korea,', 'Korea,', 'NNP', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('its', 'its', 'PRP$', 'B-NP', 'O')
('incidence', 'incidence', 'NN', 'I-NP', 'O')
('continues', 'continue', 'VBZ', 'B-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('rise', 'rise', 'VB', 'I-VP', 'O')
('(Shin', '(Shin', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2007).', '2007).', 'CD', 'B-NP', 'O')
Nevertheless, prognosis of lung cancer remains largely poor despite innovations in diagnostic testing, surgical technique, and development of new chemotherapeutic agents.
('Nevertheless,', 'Nevertheless,', 'NN', 'B-NP', 'O')
('prognosis', 'prognosis', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('remains', 'remain', 'VBZ', 'B-VP', 'O')
('largely', 'largely', 'RB', 'B-ADJP', 'O')
('poor', 'poor', 'JJ', 'I-ADJP', 'O')
('despite', 'despite', 'IN', 'B-PP', 'O')
('innovations', 'innovation', 'NNS', 'B-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('diagnostic', 'diagnostic', 'JJ', 'B-NP', 'O')
('testing,', 'testing,', 'NN', 'I-NP', 'O')
('surgical', 'surgical', 'JJ', 'I-NP', 'O')
('technique,', 'technique,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('development', 'development', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('new', 'new', 'JJ', 'B-NP', 'O')
('chemotherapeutic', 'chemotherapeutic', 'JJ', 'I-NP', 'O')
('agents.', 'agents.', 'NNS', 'I-NP', 'O')
Recently introduced targeted agents show different response according to histologic subtype, and the efficiency of treatment modalities for lung cancer depends on the time of diagnosis (Brambilla et al., 2001).
('Recently', 'Recently', 'RB', 'B-NP', 'O')
('introduced', 'introduce', 'VBN', 'I-NP', 'O')
('targeted', 'target', 'VBN', 'I-NP', 'O')
('agents', 'agent', 'NNS', 'I-NP', 'O')
('show', 'show', 'VBP', 'B-VP', 'O')
('different', 'different', 'JJ', 'B-NP', 'O')
('response', 'response', 'NN', 'I-NP', 'O')
('according', 'accord', 'VBG', 'B-PP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('histologic', 'histologic', 'JJ', 'B-NP', 'O')
('subtype,', 'subtype,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('efficiency', 'efficiency', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('treatment', 'treatment', 'NN', 'B-NP', 'O')
('modalities', 'modality', 'NNS', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('depends', 'depend', 'VBZ', 'B-VP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('time', 'time', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('diagnosis', 'diagnosis', 'NN', 'B-NP', 'O')
('(Brambilla', '(Brambilla', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2001).', '2001).', 'CD', 'B-NP', 'O')
Therefore, there is a great need for rapid and efficient early detection methods.
('Therefore,', 'Therefore,', 'IN', 'B-SBAR', 'O')
('there', 'there', 'EX', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('great', 'great', 'JJ', 'I-NP', 'O')
('need', 'need', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('rapid', 'rapid', 'JJ', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('efficient', 'efficient', 'JJ', 'I-NP', 'O')
('early', 'early', 'JJ', 'I-NP', 'O')
('detection', 'detection', 'NN', 'I-NP', 'O')
('methods.', 'methods.', 'NN', 'I-NP', 'O')
Therefore, in order to develop improved molecular biomarkers for early detection and prediction of response to chemotherapy, it is important to identify genetic alterations specific to each subtype of lung cancer.
('Therefore,', 'Therefore,', 'NN', 'B-NP', 'O')
('in', 'in', 'IN', 'B-SBAR', 'O')
('order', 'order', 'NN', 'O', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('develop', 'develop', 'VB', 'I-VP', 'O')
('improved', 'improve', 'VBN', 'B-NP', 'O')
('molecular', 'molecular', 'JJ', 'I-NP', 'O')
('biomarkers', 'biomarker', 'NNS', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('early', 'early', 'JJ', 'B-NP', 'O')
('detection', 'detection', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('prediction', 'prediction', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('response', 'response', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('chemotherapy,', 'chemotherapy,', 'VB', 'I-VP', 'O')
('it', 'it', 'PRP', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('important', 'important', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('identify', 'identify', 'VB', 'I-VP', 'O')
('genetic', 'genetic', 'JJ', 'B-NP', 'O')
('alterations', 'alteration', 'NNS', 'I-NP', 'O')
('specific', 'specific', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('each', 'each', 'DT', 'B-NP', 'O')
('subtype', 'subtype', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'O')
('cancer.', 'cancer.', 'NN', 'I-NP', 'O')
Single nucleotide polymorphisms (SNPs) have an excellent potential to be used as biomarkers for diagnosing genetic diseases, including cancers, compared to other less common polymorphisms and microsatellite markers.
('Single', 'Single', 'JJ', 'B-NP', 'O')
('nucleotide', 'nucleotide', 'NN', 'I-NP', 'O')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'O')
('(SNPs)', '(SNPs)', 'NN', 'I-NP', 'B-protein')
('have', 'have', 'VBP', 'B-VP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('excellent', 'excellent', 'JJ', 'I-NP', 'O')
('potential', 'potential', 'NN', 'I-NP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('used', 'use', 'VBN', 'I-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('biomarkers', 'biomarker', 'NNS', 'B-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('diagnosing', 'diagnose', 'VBG', 'B-VP', 'O')
('genetic', 'genetic', 'JJ', 'B-NP', 'O')
('diseases,', 'diseases,', 'NN', 'I-NP', 'O')
('including', 'include', 'VBG', 'B-PP', 'O')
('cancers,', 'cancers,', 'NN', 'B-NP', 'O')
('compared', 'compare', 'VBN', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('other', 'other', 'JJ', 'B-NP', 'O')
('less', 'less', 'RBR', 'I-NP', 'O')
('common', 'common', 'JJ', 'I-NP', 'O')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('microsatellite', 'microsatellite', 'NN', 'B-NP', 'O')
('markers.', 'markers.', 'NNS', 'I-NP', 'O')
Phosphatidylinositol 3kinases (PI3Ks) are a family of lipid protein kinases that regulate various cellular functions, including cell proliferation, survival, motility, and adhesion (Engelman et al., 2006).
('Phosphatidylinositol', 'Phosphatidylinositol', 'NN', 'B-NP', 'B-protein')
('3kinases', '3kinas', 'NNS', 'I-NP', 'I-protein')
('(PI3Ks)', '(PI3Ks)', 'NN', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('family', 'family', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('lipid', 'lipid', 'NN', 'B-NP', 'B-protein')
('protein', 'protein', 'NN', 'I-NP', 'I-protein')
('kinases', 'kinase', 'NNS', 'I-NP', 'I-protein')
('that', 'that', 'WDT', 'B-NP', 'O')
('regulate', 'regulate', 'VBP', 'B-VP', 'O')
('various', 'various', 'JJ', 'B-NP', 'O')
('cellular', 'cellular', 'JJ', 'I-NP', 'O')
('functions,', 'functions,', 'NN', 'I-NP', 'O')
('including', 'include', 'VBG', 'B-PP', 'O')
('cell', 'cell', 'NN', 'B-NP', 'O')
('proliferation,', 'proliferation,', 'NN', 'I-NP', 'O')
('survival,', 'survival,', 'NN', 'I-NP', 'O')
('motility,', 'motility,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('adhesion', 'adhesion', 'NN', 'I-NP', 'O')
('(Engelman', '(Engelman', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2006).', '2006).', 'CD', 'B-NP', 'O')
The PIK3CA gene encodes a catalytic subunit p110α of class IA PI3Ks that is located in the downstream signaling pathway of growth factor receptors, such as EGFR and HER2 oncoproteins; the pathway is negatively regulated by the PTEN tumor suppressor protein.
('The', 'The', 'DT', 'B-NP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'I-NP', 'B-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('encodes', 'encode', 'VBZ', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('catalytic', 'catalytic', 'JJ', 'I-NP', 'B-protein')
('subunit', 'subunit', 'NN', 'I-NP', 'I-protein')
('p110α', 'p110α', 'NN', 'I-NP', 'I-protein')
('of', 'of', 'IN', 'B-PP', 'O')
('class', 'class', 'NN', 'B-NP', 'B-protein')
('IA', 'IA', 'NN', 'I-NP', 'I-protein')
('PI3Ks', 'PI3K', 'NNS', 'I-NP', 'I-protein')
('that', 'that', 'WDT', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('located', 'located', 'JJ', 'B-ADJP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('downstream', 'downstream', 'JJ', 'I-NP', 'O')
('signaling', 'signaling', 'NN', 'I-NP', 'O')
('pathway', 'pathway', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('growth', 'growth', 'NN', 'B-NP', 'B-protein')
('factor', 'factor', 'NN', 'I-NP', 'I-protein')
('receptors,', 'receptors,', 'NN', 'I-NP', 'O')
('such', 'such', 'JJ', 'B-PP', 'O')
('as', 'as', 'IN', 'I-PP', 'O')
('EGFR', 'EGFR', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('HER2', 'HER2', 'NN', 'I-NP', 'B-protein')
('oncoproteins;', 'oncoproteins;', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('pathway', 'pathway', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('negatively', 'negatively', 'RB', 'I-VP', 'O')
('regulated', 'regulate', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('PTEN', 'PTEN', 'NN', 'I-NP', 'O')
('tumor', 'tumor', 'NN', 'I-NP', 'O')
('suppressor', 'suppressor', 'NN', 'I-NP', 'O')
('protein.', 'protein.', 'NN', 'I-NP', 'O')
One of the most important downstream targets of the p110α complex in cancer is AKT, which upregulates cell survival, proliferation, and growth signaling through phosphorylating multiple substrates, including apoptosisrelated proteins (BAD and FKHR) and the mTOR complex components (PRAS40 and mTOR) (Manning and Cantley, 2007).
('One', 'One', 'CD', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('most', 'most', 'RBS', 'I-NP', 'O')
('important', 'important', 'JJ', 'I-NP', 'O')
('downstream', 'downstream', 'JJ', 'I-NP', 'O')
('targets', 'target', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('p110α', 'p110α', 'NN', 'I-NP', 'B-protein')
('complex', 'complex', 'NN', 'I-NP', 'I-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('cancer', 'cancer', 'NN', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('AKT,', 'AKT,', 'NNP', 'B-NP', 'O')
('which', 'which', 'WDT', 'B-NP', 'O')
('upregulates', 'upregulate', 'VBZ', 'B-VP', 'O')
('cell', 'cell', 'NN', 'B-NP', 'O')
('survival,', 'survival,', 'NN', 'I-NP', 'O')
('proliferation,', 'proliferation,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('growth', 'growth', 'NN', 'I-NP', 'O')
('signaling', 'signaling', 'NN', 'I-NP', 'O')
('through', 'through', 'IN', 'B-PP', 'O')
('phosphorylating', 'phosphorylate', 'VBG', 'B-VP', 'O')
('multiple', 'multiple', 'JJ', 'B-NP', 'O')
('substrates,', 'substrates,', 'NN', 'I-NP', 'O')
('including', 'include', 'VBG', 'B-PP', 'O')
('apoptosisrelated', 'apoptosisrelated', 'JJ', 'B-NP', 'O')
('proteins', 'protein', 'NNS', 'I-NP', 'O')
('(BAD', '(BAD', 'NN', 'I-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('FKHR)', 'FKHR)', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mTOR', 'mTOR', 'NN', 'I-NP', 'B-protein')
('complex', 'complex', 'NN', 'I-NP', 'I-protein')
('components', 'component', 'NNS', 'I-NP', 'O')
('(PRAS40', '(PRAS40', 'NN', 'I-NP', 'B-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('mTOR)', 'mTOR)', 'NN', 'I-NP', 'O')
('(Manning', '(Manning', 'NNP', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Cantley,', 'Cantley,', 'NNP', 'B-NP', 'O')
('2007).', '2007).', 'CD', 'I-NP', 'O')
Somatic mutations of the PIK3CA gene have been reported in a wide range of human cancers, being especially frequent in breast, colorectal, ovary and liver tumors (Karakas et al., 2006).
('Somatic', 'Somatic', 'JJ', 'B-NP', 'O')
('mutations', 'mutation', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'I-NP', 'B-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('have', 'have', 'VBP', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('reported', 'report', 'VBN', 'I-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('wide', 'wide', 'JJ', 'I-NP', 'O')
('range', 'range', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('human', 'human', 'JJ', 'B-NP', 'O')
('cancers,', 'cancers,', 'NN', 'I-NP', 'O')
('being', 'be', 'VBG', 'B-VP', 'O')
('especially', 'especially', 'RB', 'B-ADJP', 'O')
('frequent', 'frequent', 'JJ', 'I-ADJP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('breast,', 'breast,', 'NN', 'B-NP', 'O')
('colorectal,', 'colorectal,', 'NN', 'I-NP', 'O')
('ovary', 'ovary', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('liver', 'liver', 'NN', 'B-NP', 'O')
('tumors', 'tumor', 'NNS', 'I-NP', 'O')
('(Karakas', '(Karakas', 'NNP', 'I-NP', 'O')
('et', 'et', 'NN', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2006).', '2006).', 'CD', 'B-NP', 'O')
Mutation of the PIK3CA is likely to function as an oncogene in human cancers (Kang et al., 2005), however, the mutation rate shown in lung cancer is relatively low (Kawano et al., 2006; Lee et al., 2005; Samuels et al., 2004).
('Mutation', 'Mutation', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'I-NP', 'B-protein')
('is', 'be', 'VBZ', 'B-VP', 'O')
('likely', 'likely', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('function', 'function', 'VB', 'I-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('oncogene', 'oncogene', 'NN', 'I-NP', 'B-DNA')
('in', 'in', 'IN', 'B-PP', 'O')
('human', 'human', 'JJ', 'B-NP', 'O')
('cancers', 'cancer', 'NNS', 'I-NP', 'O')
('(Kang', '(Kang', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'NN', 'I-NP', 'O')
('2005),', '2005),', 'VBD', 'B-VP', 'O')
('however,', 'however,', 'NN', 'B-NP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('mutation', 'mutation', 'NN', 'I-NP', 'O')
('rate', 'rate', 'NN', 'I-NP', 'O')
('shown', 'show', 'VBN', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('relatively', 'relatively', 'RB', 'B-NP', 'O')
('low', 'low', 'JJ', 'I-NP', 'O')
('(Kawano', '(Kawano', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'VBD', 'B-VP', 'O')
('2006;', '2006;', ':', 'O', 'O')
('Lee', 'Lee', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'VBD', 'B-VP', 'O')
('2005;', '2005;', ':', 'O', 'O')
('Samuels', 'Samuels', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2004).', '2004).', 'CD', 'B-NP', 'O')
Furthermore, mutation and copy number gain of the PIK3CA gene have been reported to be associated with lung cancer (Massion et al., 2002; Yamamoto et al., 2008), nevertheless, the association between polymorphism and the risk of lung cancer has not yet been fully clarified.
('Furthermore,', 'Furthermore,', 'NN', 'B-NP', 'O')
('mutation', 'mutation', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('copy', 'copy', 'NN', 'I-NP', 'O')
('number', 'number', 'NN', 'I-NP', 'O')
('gain', 'gain', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'I-NP', 'B-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('have', 'have', 'VBP', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('reported', 'report', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'B-protein')
('cancer', 'cancer', 'NN', 'I-NP', 'I-protein')
('(Massion', '(Massion', 'NN', 'I-NP', 'I-protein')
('et', 'et', 'FW', 'B-ADVP', 'I-protein')
('al.,', 'al.,', 'FW', 'I-ADVP', 'I-protein')
('2002;', '2002;', ':', 'O', 'I-protein')
('Yamamoto', 'Yamamoto', 'NNP', 'B-NP', 'I-protein')
('et', 'et', 'NNP', 'I-NP', 'I-protein')
('al.,', 'al.,', 'NN', 'I-NP', 'I-protein')
('2008),', '2008),', 'VBD', 'B-VP', 'O')
('nevertheless,', 'nevertheless,', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('polymorphism', 'polymorphism', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('risk', 'risk', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('has', 'have', 'VBZ', 'B-VP', 'O')
('not', 'not', 'RB', 'I-VP', 'O')
('yet', 'yet', 'RB', 'I-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('fully', 'fully', 'RB', 'I-VP', 'O')
('clarified.', 'clarified.', 'VBN', 'I-VP', 'O')
This study was undertaken to examine the polymorphism of PIK3CA, and its relation with the risk of lung cancer in Korean population.
('This', 'This', 'DT', 'B-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('undertaken', 'undertake', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('examine', 'examine', 'VB', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('polymorphism', 'polymorphism', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('PIK3CA,', 'PIK3CA,', 'NN', 'B-NP', 'B-protein')
('and', 'and', 'CC', 'O', 'O')
('its', 'its', 'PRP$', 'B-NP', 'O')
('relation', 'relation', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('risk', 'risk', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Korean', 'Korean', 'JJ', 'B-NP', 'O')
('population.', 'population.', 'NN', 'I-NP', 'O')
To our best knowledge, this is the first report on the polymorphism of PIK3CA in lung cancer patients in Korean population.
('To', 'To', 'TO', 'B-PP', 'O')
('our', 'our', 'PRP$', 'B-NP', 'O')
('best', 'good', 'JJS', 'I-NP', 'O')
('knowledge,', 'knowledge,', 'NN', 'I-NP', 'O')
('this', 'this', 'DT', 'B-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('first', 'first', 'JJ', 'I-NP', 'O')
('report', 'report', 'NN', 'I-NP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('polymorphism', 'polymorphism', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'B-NP', 'B-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Korean', 'Korean', 'JJ', 'B-NP', 'O')
('population.', 'population.', 'NN', 'I-NP', 'O')
Between August 2001 and November 2007, blood sam  ples were collected from 866 subjects, including 423 lung cancer patients and 443 normal controls without cancer.
('Between', 'Between', 'IN', 'B-PP', 'O')
('August', 'August', 'NNP', 'B-NP', 'O')
('2001', '2001', 'CD', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('November', 'November', 'NNP', 'B-NP', 'O')
('2007,', '2007,', 'CD', 'I-NP', 'O')
('blood', 'blood', 'NN', 'I-NP', 'O')
('sam', 'sam', 'NN', 'I-NP', 'O')
('ples', 'ple', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('collected', 'collect', 'VBN', 'I-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('866', '866', 'CD', 'B-NP', 'O')
('subjects,', 'subjects,', 'NN', 'I-NP', 'O')
('including', 'include', 'VBG', 'B-PP', 'O')
('423', '423', 'CD', 'B-NP', 'O')
('lung', 'lung', 'NN', 'I-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('443', '443', 'CD', 'B-NP', 'O')
('normal', 'normal', 'JJ', 'I-NP', 'O')
('controls', 'control', 'NNS', 'I-NP', 'O')
('without', 'without', 'IN', 'B-PP', 'O')
('cancer.', 'cancer.', 'NN', 'B-NP', 'O')
Lung cancer patients were recruited from the patient pool at the Genomic Research Center for Lung and Breast/Ovarian Cancer, and control subjects were randomly selected from a pool of healthy volunteers who had visited the Cardiovascular Genome Center and Genomic Research Center for Allergy and Respiratory Diseases.
('Lung', 'Lung', 'NN', 'B-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('recruited', 'recruit', 'VBN', 'I-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('patient', 'patient', 'NN', 'I-NP', 'O')
('pool', 'pool', 'NN', 'I-NP', 'O')
('at', 'at', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Genomic', 'Genomic', 'NNP', 'I-NP', 'O')
('Research', 'Research', 'NNP', 'I-NP', 'O')
('Center', 'Center', 'NNP', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('Lung', 'Lung', 'NNP', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Breast/Ovarian', 'Breast/Ovarian', 'NNP', 'B-NP', 'O')
('Cancer,', 'Cancer,', 'NNP', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('control', 'control', 'JJ', 'B-NP', 'O')
('subjects', 'subject', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('randomly', 'randomly', 'RB', 'I-VP', 'O')
('selected', 'select', 'VBN', 'I-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('pool', 'pool', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('healthy', 'healthy', 'JJ', 'B-NP', 'O')
('volunteers', 'volunteer', 'NNS', 'I-NP', 'O')
('who', 'who', 'WP', 'B-NP', 'O')
('had', 'have', 'VBD', 'B-VP', 'O')
('visited', 'visit', 'VBN', 'I-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Cardiovascular', 'Cardiovascular', 'NNP', 'I-NP', 'O')
('Genome', 'Genome', 'NNP', 'I-NP', 'O')
('Center', 'Center', 'NNP', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Genomic', 'Genomic', 'NNP', 'B-NP', 'O')
('Research', 'Research', 'NNP', 'I-NP', 'O')
('Center', 'Center', 'NNP', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('Allergy', 'Allergy', 'NNP', 'B-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Respiratory', 'Respiratory', 'NNP', 'B-NP', 'O')
('Diseases.', 'Diseases.', 'NNP', 'I-NP', 'O')
Detailed information on diet, smoking status, drinking status, lifestyle, and medical history were collected by a trained interviewer using a structured questionnaire.
('Detailed', 'Detailed', 'JJ', 'B-NP', 'O')
('information', 'information', 'NN', 'I-NP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('diet,', 'diet,', 'NN', 'B-NP', 'O')
('smoking', 'smoking', 'NN', 'I-NP', 'O')
('status,', 'status,', 'NN', 'I-NP', 'O')
('drinking', 'drinking', 'NN', 'I-NP', 'O')
('status,', 'status,', 'NN', 'I-NP', 'O')
('lifestyle,', 'lifestyle,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('medical', 'medical', 'JJ', 'B-NP', 'O')
('history', 'history', 'NN', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('collected', 'collect', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('trained', 'trained', 'JJ', 'I-NP', 'O')
('interviewer', 'interviewer', 'NN', 'I-NP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('structured', 'structured', 'JJ', 'I-NP', 'O')
('questionnaire.', 'questionnaire.', 'NN', 'I-NP', 'O')
Out of 423 cases, 413 smoking status, 335 stage, and 407 cell types were available for characteristic information, while 341 smoking status out of 443 controls were available for characteristic information (Table 1).
('Out', 'Out', 'IN', 'B-PP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('423', '423', 'CD', 'B-NP', 'O')
('cases,', 'cases,', 'NN', 'I-NP', 'O')
('413', '413', 'CD', 'B-NP', 'O')
('smoking', 'smoking', 'NN', 'I-NP', 'O')
('status,', 'status,', 'NN', 'I-NP', 'O')
('335', '335', 'CD', 'I-NP', 'O')
('stage,', 'stage,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('407', '407', 'CD', 'B-NP', 'O')
('cell', 'cell', 'NN', 'I-NP', 'O')
('types', 'type', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('available', 'available', 'JJ', 'B-ADJP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('characteristic', 'characteristic', 'JJ', 'B-NP', 'O')
('information,', 'information,', 'NN', 'I-NP', 'O')
('while', 'while', 'IN', 'B-SBAR', 'O')
('341', '341', 'CD', 'B-NP', 'O')
('smoking', 'smoking', 'NN', 'I-NP', 'O')
('status', 'status', 'NN', 'I-NP', 'O')
('out', 'out', 'IN', 'B-PP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('443', '443', 'CD', 'B-NP', 'O')
('controls', 'control', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('available', 'available', 'JJ', 'B-ADJP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('characteristic', 'characteristic', 'JJ', 'B-NP', 'O')
('information', 'information', 'NN', 'I-NP', 'O')
('(Table', '(Table', 'JJ', 'I-NP', 'O')
('1).', '1).', 'CD', 'I-NP', 'O')
All study subjects provided written consents and were ethnic Koreans, and all the participating Institutional Review Boards approved the study protocol.
('All', 'All', 'DT', 'B-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('subjects', 'subject', 'NNS', 'I-NP', 'O')
('provided', 'provide', 'VBD', 'B-VP', 'O')
('written', 'write', 'VBN', 'B-NP', 'O')
('consents', 'consent', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('ethnic', 'ethnic', 'JJ', 'B-NP', 'O')
('Koreans,', 'Koreans,', 'NNP', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('all', 'all', 'PDT', 'B-NP', 'O')
('the', 'the', 'DT', 'I-NP', 'O')
('participating', 'participate', 'VBG', 'I-NP', 'O')
('Institutional', 'Institutional', 'NNP', 'I-NP', 'O')
('Review', 'Review', 'NNP', 'I-NP', 'O')
('Boards', 'Boards', 'NNP', 'I-NP', 'O')
('approved', 'approve', 'VBD', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('protocol.', 'protocol.', 'NN', 'I-NP', 'O')
Genomic DNA was prepared from peripheral blood samples using a Puregene blood DNA kit (Gentra, Minneapolis, MN, USA), according to the manufacture’s protocol.
('Genomic', 'Genomic', 'JJ', 'B-NP', 'B-DNA')
('DNA', 'DNA', 'NN', 'I-NP', 'I-DNA')
('was', 'be', 'VBD', 'B-VP', 'O')
('prepared', 'prepare', 'VBN', 'I-VP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('peripheral', 'peripheral', 'JJ', 'B-NP', 'B-cell_type')
('blood', 'blood', 'NN', 'I-NP', 'I-cell_type')
('samples', 'sample', 'NNS', 'I-NP', 'I-cell_type')
('using', 'use', 'VBG', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('Puregene', 'Puregene', 'NN', 'I-NP', 'O')
('blood', 'blood', 'NN', 'I-NP', 'O')
('DNA', 'DNA', 'NN', 'I-NP', 'O')
('kit', 'kit', 'NN', 'I-NP', 'O')
('(Gentra,', '(Gentra,', 'NNP', 'I-NP', 'O')
('Minneapolis,', 'Minneapolis,', 'NNP', 'I-NP', 'O')
('MN,', 'MN,', 'NNP', 'I-NP', 'O')
('USA),', 'USA),', 'NNP', 'I-NP', 'O')
('according', 'accord', 'VBG', 'B-PP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('manufacture’s', 'manufacture’', 'NNS', 'I-NP', 'O')
('protocol.', 'protocol.', 'NN', 'I-NP', 'O')
We performed genotyping for the five polymorphisms (rs11709323, rs2699895, rs3729679, rs17849074 and rs1356413).
('We', 'We', 'PRP', 'B-NP', 'O')
('performed', 'perform', 'VBD', 'B-VP', 'O')
('genotyping', 'genotype', 'VBG', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('five', 'five', 'CD', 'I-NP', 'O')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'O')
('(rs11709323,', '(rs11709323,', 'VBD', 'B-VP', 'O')
('rs2699895,', 'rs2699895,', 'NN', 'B-NP', 'O')
('rs3729679,', 'rs3729679,', 'NN', 'I-NP', 'O')
('rs17849074', 'rs17849074', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('rs1356413).', 'rs1356413).', 'NN', 'B-NP', 'O')
Genotyping was done by the SNPIT assay using the SNPstream 25K System (Orchid Biosciences, Princeton, NJ, USA).
('Genotyping', 'Genotyping', 'NN', 'B-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('done', 'do', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('SNPIT', 'SNPIT', 'NN', 'I-NP', 'O')
('assay', 'assay', 'NN', 'I-NP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('SNPstream', 'SNPstream', 'NNP', 'I-NP', 'O')
('25K', '25K', 'NNP', 'I-NP', 'O')
('System', 'System', 'NNP', 'I-NP', 'O')
('(Orchid', '(Orchid', 'NNP', 'I-NP', 'O')
('Biosciences,', 'Biosciences,', 'NNP', 'I-NP', 'O')
('Princeton,', 'Princeton,', 'NNP', 'I-NP', 'O')
('NJ,', 'NJ,', 'NNP', 'I-NP', 'O')
('USA).', 'USA).', 'NNP', 'I-NP', 'O')
Briefly, the genomic DNA region spanning the polymorphic site was amplified polymerase chain reaction (PCR) by one phosphothiolated primer and one regular PCR primer.
('Briefly,', 'Briefly,', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('genomic', 'genomic', 'JJ', 'I-NP', 'B-DNA')
('DNA', 'DNA', 'NN', 'I-NP', 'I-DNA')
('region', 'region', 'NN', 'I-NP', 'I-DNA')
('spanning', 'span', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('polymorphic', 'polymorphic', 'JJ', 'I-NP', 'B-DNA')
('site', 'site', 'NN', 'I-NP', 'I-DNA')
('was', 'be', 'VBD', 'B-VP', 'O')
('amplified', 'amplify', 'VBN', 'I-VP', 'O')
('polymerase', 'polymerase', 'NN', 'B-NP', 'O')
('chain', 'chain', 'NN', 'I-NP', 'O')
('reaction', 'reaction', 'NN', 'I-NP', 'O')
('(PCR)', '(PCR)', 'NN', 'I-NP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('one', 'one', 'CD', 'B-NP', 'O')
('phosphothiolated', 'phosphothiolated', 'JJ', 'I-NP', 'O')
('primer', 'primer', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('one', 'one', 'CD', 'B-NP', 'O')
('regular', 'regular', 'JJ', 'I-NP', 'O')
('PCR', 'PCR', 'NN', 'I-NP', 'O')
('primer.', 'primer.', 'NN', 'I-NP', 'O')
The amplified PCR products were then digested with T7 exonuclease.
('The', 'The', 'DT', 'B-NP', 'O')
('amplified', 'amplify', 'VBN', 'I-NP', 'O')
('PCR', 'PCR', 'NN', 'I-NP', 'B-DNA')
('products', 'product', 'NNS', 'I-NP', 'I-DNA')
('were', 'be', 'VBD', 'B-VP', 'O')
('then', 'then', 'RB', 'I-VP', 'O')
('digested', 'digest', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('T7', 'T7', 'NN', 'B-NP', 'O')
('exonuclease.', 'exonuclease.', 'NN', 'I-NP', 'O')
The 5' phosphothiolates protected one strand of the PCR product from T7 exonuclease digestion, resulting in the generation of a singlestranded PCR template.
('The', 'The', 'DT', 'B-NP', 'O')
("5'", "5'", 'JJ', 'I-NP', 'O')
('phosphothiolates', 'phosphothiolate', 'NNS', 'I-NP', 'O')
('protected', 'protect', 'VBD', 'B-VP', 'O')
('one', 'one', 'CD', 'B-NP', 'O')
('strand', 'strand', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('PCR', 'PCR', 'NN', 'I-NP', 'B-DNA')
('product', 'product', 'NN', 'I-NP', 'I-DNA')
('from', 'from', 'IN', 'B-PP', 'O')
('T7', 'T7', 'NN', 'B-NP', 'B-protein')
('exonuclease', 'exonuclease', 'NN', 'I-NP', 'I-protein')
('digestion,', 'digestion,', 'NN', 'I-NP', 'O')
('resulting', 'result', 'VBG', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('generation', 'generation', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('singlestranded', 'singlestranded', 'JJ', 'I-NP', 'O')
('PCR', 'PCR', 'NN', 'I-NP', 'O')
('template.', 'template.', 'NN', 'I-NP', 'O')
The singlestranded PCR template was overlaid on a 384well plate that contained a covalently attached SNPIT pri  　　　　mer extension primer designed to hybridize immediately adjacent to the polymorphic site.
('The', 'The', 'DT', 'B-NP', 'O')
('singlestranded', 'singlestranded', 'JJ', 'I-NP', 'O')
('PCR', 'PCR', 'NN', 'I-NP', 'O')
('template', 'template', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('overlaid', 'overlay', 'VBN', 'I-VP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('384well', '384well', 'NN', 'I-NP', 'O')
('plate', 'plate', 'NN', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('contained', 'contain', 'VBD', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('covalently', 'covalently', 'RB', 'I-NP', 'O')
('attached', 'attach', 'VBN', 'I-NP', 'O')
('SNPIT', 'SNPIT', 'NN', 'I-NP', 'O')
('pri', 'pri', 'NN', 'I-NP', 'O')
('\u3000\u3000\u3000\u3000mer', '\u3000\u3000\u3000\u3000mer', 'NN', 'I-NP', 'O')
('extension', 'extension', 'NN', 'I-NP', 'O')
('primer', 'primer', 'NN', 'I-NP', 'O')
('designed', 'design', 'VBN', 'B-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('hybridize', 'hybridize', 'VB', 'I-VP', 'O')
('immediately', 'immediately', 'RB', 'B-ADJP', 'O')
('adjacent', 'adjacent', 'JJ', 'I-ADJP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('polymorphic', 'polymorphic', 'JJ', 'I-NP', 'O')
('site.', 'site.', 'NN', 'I-NP', 'O')
The SNPIT primer was extended for a single base with DNA polymerase and a mixture of appropriate acycloterminators complementary to the polymorphic nucleotide that were labeled with either fluorescein isothiocyanate (FITC) or biotin.
('The', 'The', 'DT', 'B-NP', 'O')
('SNPIT', 'SNPIT', 'NN', 'I-NP', 'O')
('primer', 'primer', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('extended', 'extend', 'VBN', 'I-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('single', 'single', 'JJ', 'I-NP', 'O')
('base', 'base', 'NN', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('DNA', 'DNA', 'NN', 'B-NP', 'B-protein')
('polymerase', 'polymerase', 'NN', 'I-NP', 'I-protein')
('and', 'and', 'CC', 'O', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('mixture', 'mixture', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('appropriate', 'appropriate', 'JJ', 'B-NP', 'O')
('acycloterminators', 'acycloterminator', 'NNS', 'I-NP', 'O')
('complementary', 'complementary', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('polymorphic', 'polymorphic', 'JJ', 'I-NP', 'O')
('nucleotide', 'nucleotide', 'NN', 'I-NP', 'O')
('that', 'that', 'WDT', 'B-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('labeled', 'label', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('either', 'either', 'CC', 'O', 'O')
('fluorescein', 'fluorescein', 'NN', 'B-NP', 'O')
('isothiocyanate', 'isothiocyanate', 'NN', 'I-NP', 'O')
('(FITC)', '(FITC)', 'NN', 'I-NP', 'O')
('or', 'or', 'CC', 'O', 'O')
('biotin.', 'biotin.', 'NN', 'B-NP', 'O')
The identity of the incorporated nucleotide was determined by serial colorimetric reactions with anti FITC-AP and streptavidin-horseradish peroxidase, respectively.
('The', 'The', 'DT', 'B-NP', 'O')
('identity', 'identity', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('incorporated', 'incorporated', 'JJ', 'I-NP', 'O')
('nucleotide', 'nucleotide', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('determined', 'determine', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('serial', 'serial', 'JJ', 'B-NP', 'O')
('colorimetric', 'colorimetric', 'JJ', 'I-NP', 'O')
('reactions', 'reaction', 'NNS', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('anti', 'anti', 'JJ', 'B-NP', 'B-protein')
('FITC-AP', 'FITC-AP', 'NN', 'I-NP', 'I-protein')
('and', 'and', 'CC', 'O', 'O')
('streptavidin-horseradish', 'streptavidin-horseradish', 'JJ', 'B-NP', 'O')
('peroxidase,', 'peroxidase,', 'NN', 'I-NP', 'O')
('respectively.', 'respectively.', 'NN', 'I-NP', 'O')
Resultant yellow and/or blue color development was analyzed using an ELISA reader, and the final genotype calls were made using a QCReview program (Orchid Biosciences).
('Resultant', 'Resultant', 'JJ', 'B-NP', 'O')
('yellow', 'yellow', 'JJ', 'I-NP', 'O')
('and/or', 'and/or', 'CC', 'I-NP', 'O')
('blue', 'blue', 'JJ', 'I-NP', 'O')
('color', 'color', 'NN', 'I-NP', 'O')
('development', 'development', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('analyzed', 'analyze', 'VBN', 'I-VP', 'O')
('using', 'use', 'VBG', 'I-VP', 'O')
('an', 'an', 'DT', 'B-NP', 'O')
('ELISA', 'ELISA', 'NN', 'I-NP', 'O')
('reader,', 'reader,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('final', 'final', 'JJ', 'I-NP', 'O')
('genotype', 'genotype', 'NN', 'I-NP', 'O')
('calls', 'call', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('made', 'make', 'VBN', 'I-VP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('QCReview', 'QCReview', 'NNP', 'I-NP', 'O')
('program', 'program', 'NN', 'I-NP', 'O')
('(Orchid', '(Orchid', 'NNP', 'I-NP', 'O')
('Biosciences).', 'Biosciences).', 'NNP', 'I-NP', 'O')
Allele frequencies, genotype frequencies, and departures of genotype distributions from Hardy-Weinberg equilibrium for each SNP were analyzed using the chisquare test or Fisher’s exact test.
('Allele', 'Allele', 'NN', 'B-NP', 'B-DNA')
('frequencies,', 'frequencies,', 'NN', 'I-NP', 'O')
('genotype', 'genotype', 'NN', 'I-NP', 'O')
('frequencies,', 'frequencies,', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('departures', 'departure', 'NNS', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('genotype', 'genotype', 'NN', 'B-NP', 'O')
('distributions', 'distribution', 'NNS', 'I-NP', 'O')
('from', 'from', 'IN', 'B-PP', 'O')
('Hardy-Weinberg', 'Hardy-Weinberg', 'JJ', 'B-NP', 'O')
('equilibrium', 'equilibrium', 'NN', 'I-NP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('each', 'each', 'DT', 'B-NP', 'O')
('SNP', 'SNP', 'NN', 'I-NP', 'B-protein')
('were', 'be', 'VBD', 'B-VP', 'O')
('analyzed', 'analyze', 'VBN', 'I-VP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('chisquare', 'chisquare', 'NN', 'I-NP', 'O')
('test', 'test', 'NN', 'I-NP', 'O')
('or', 'or', 'CC', 'I-NP', 'O')
('Fisher’s', 'Fisher’', 'NNS', 'I-NP', 'O')
('exact', 'exact', 'VBP', 'B-VP', 'O')
('test.', 'test.', 'NN', 'B-NP', 'O')
A p-value of ＜0.05 was considered statistically significant.
('A', 'A', 'DT', 'B-NP', 'O')
('p-value', 'p-value', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('＜0.05', '＜0.05', 'NN', 'B-NP', 'B-protein')
('was', 'be', 'VBD', 'B-VP', 'O')
('considered', 'consider', 'VBN', 'I-VP', 'O')
('statistically', 'statistically', 'RB', 'B-ADVP', 'O')
('significant.', 'significant.', 'RB', 'I-ADVP', 'O')
Linkage disequilibrium (LD) was tested on pairwise combinations of polymorphisms using the absolute value of the standardized measure of LD, D’ calculated by the Haploview program version 3.2.
('Linkage', 'Linkage', 'NN', 'B-NP', 'O')
('disequilibrium', 'disequilibrium', 'NN', 'I-NP', 'O')
('(LD)', '(LD)', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('tested', 'test', 'VBN', 'I-VP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('pairwise', 'pairwise', 'JJ', 'B-NP', 'O')
('combinations', 'combination', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('polymorphisms', 'polymorphism', 'NNS', 'B-NP', 'O')
('using', 'use', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('absolute', 'absolute', 'JJ', 'I-NP', 'O')
('value', 'value', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('standardized', 'standardized', 'JJ', 'I-NP', 'O')
('measure', 'measure', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('LD,', 'LD,', 'NNP', 'B-NP', 'O')
('D’', 'D’', 'NNP', 'I-NP', 'O')
('calculated', 'calculate', 'VBN', 'B-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Haploview', 'Haploview', 'NNP', 'I-NP', 'O')
('program', 'program', 'NN', 'I-NP', 'O')
('version', 'version', 'NN', 'I-NP', 'O')
('3.2.', '3.2.', 'CD', 'I-NP', 'O')
The haplotypes and their frequencies were estimated by the Haploview program version 3.2.
('The', 'The', 'DT', 'B-NP', 'O')
('haplotypes', 'haplotype', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('their', 'their', 'PRP$', 'B-NP', 'O')
('frequencies', 'frequency', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('estimated', 'estimate', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Haploview', 'Haploview', 'NNP', 'I-NP', 'O')
('program', 'program', 'NN', 'I-NP', 'O')
('version', 'version', 'NN', 'I-NP', 'O')
('3.2.', '3.2.', 'CD', 'I-NP', 'O')
Genotypespecific risks were estimated as odds ratios (ORs) with associated 95% confidence intervals by unconditional logistic regression (SAS version 9.1; SAS Institute, Cary, NC, USA) and adjusted for age, gender and smoking status.
('Genotypespecific', 'Genotypespecific', 'JJ', 'B-NP', 'O')
('risks', 'risk', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('estimated', 'estimate', 'VBN', 'I-VP', 'O')
('as', 'as', 'IN', 'B-PP', 'O')
('odds', 'odd', 'NNS', 'B-NP', 'O')
('ratios', 'ratio', 'NNS', 'I-NP', 'O')
('(ORs)', '(ORs)', 'NN', 'I-NP', 'B-protein')
('with', 'with', 'IN', 'B-PP', 'O')
('associated', 'associate', 'VBN', 'B-NP', 'O')
('95%', '95%', 'CD', 'I-NP', 'O')
('confidence', 'confidence', 'NN', 'I-NP', 'O')
('intervals', 'interval', 'NNS', 'I-NP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('unconditional', 'unconditional', 'JJ', 'B-NP', 'O')
('logistic', 'logistic', 'JJ', 'I-NP', 'O')
('regression', 'regression', 'NN', 'I-NP', 'O')
('(SAS', '(SAS', 'NN', 'I-NP', 'O')
('version', 'version', 'NN', 'I-NP', 'O')
('9.1;', '9.1;', 'CD', 'I-NP', 'O')
('SAS', 'SAS', 'NNP', 'I-NP', 'O')
('Institute,', 'Institute,', 'NNP', 'I-NP', 'O')
('Cary,', 'Cary,', 'NNP', 'I-NP', 'O')
('NC,', 'NC,', 'NNP', 'I-NP', 'O')
('USA)', 'USA)', 'NNP', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('adjusted', 'adjust', 'VBN', 'B-VP', 'O')
('for', 'for', 'IN', 'B-PP', 'O')
('age,', 'age,', 'NN', 'B-NP', 'O')
('gender', 'gender', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('smoking', 'smoking', 'NN', 'I-NP', 'O')
('status.', 'status.', 'NNS', 'I-NP', 'O')
Among 219 polymorphisms of PIK3CA gene recorded in the dbSNP (www.
('Among', 'Among', 'IN', 'B-PP', 'O')
('219', '219', 'CD', 'B-NP', 'O')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'B-NP', 'B-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('recorded', 'record', 'VBN', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('dbSNP', 'dbSNP', 'NN', 'I-NP', 'O')
('(www.', '(www.', '.', 'O', 'O')
nci.
('nci.', 'nci.', 'LS', 'B-LST', 'O')
nlm.
('nlm.', 'nlm.', 'LS', 'B-LST', 'O')
nih.
('nih.', 'nih.', 'LS', 'B-LST', 'O')
gov/SNP), five polymorphisms (rs11709323, rs2699895, rs3729679, rs17849074 and rs1356413) were selected and analyzed on the basis of reported frequency in Asian population.
('gov/SNP),', 'gov/SNP),', 'NN', 'B-NP', 'O')
('five', 'five', 'CD', 'I-NP', 'O')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'O')
('(rs11709323,', '(rs11709323,', 'VBD', 'B-VP', 'O')
('rs2699895,', 'rs2699895,', 'NN', 'B-NP', 'O')
('rs3729679,', 'rs3729679,', 'NN', 'I-NP', 'O')
('rs17849074', 'rs17849074', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('rs1356413)', 'rs1356413)', 'NN', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('selected', 'select', 'VBN', 'I-VP', 'O')
('and', 'and', 'CC', 'O', 'O')
('analyzed', 'analyze', 'VBN', 'B-VP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('basis', 'basis', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('reported', 'report', 'VBN', 'B-NP', 'O')
('frequency', 'frequency', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Asian', 'Asian', 'JJ', 'B-NP', 'O')
('population.', 'population.', 'NN', 'I-NP', 'O')
The genotype distributions of the polymorphisms among the pop  　　　　　　ulation were in Hardy-Weinberg equilibrium.
('The', 'The', 'DT', 'B-NP', 'O')
('genotype', 'genotype', 'NN', 'I-NP', 'O')
('distributions', 'distribution', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'O')
('among', 'among', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('pop', 'pop', 'NN', 'I-NP', 'O')
('\u3000\u3000\u3000\u3000\u3000\u3000ulation', '\u3000\u3000\u3000\u3000\u3000\u3000ulation', 'NN', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('Hardy-Weinberg', 'Hardy-Weinberg', 'NNP', 'B-NP', 'O')
('equilibrium.', 'equilibrium.', 'NNP', 'I-NP', 'O')
Also, LD coefficients (|D’| and r2) and haplotypes among the polymorphisms were calculated (Fig.
('Also,', 'Also,', 'IN', 'B-PP', 'O')
('LD', 'LD', 'NN', 'B-NP', 'B-protein')
('coefficients', 'coefficient', 'NNS', 'I-NP', 'I-protein')
('(|D’|', '(|D’|', 'NN', 'I-NP', 'I-protein')
('and', 'and', 'CC', 'I-NP', 'O')
('r2)', 'r2)', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('haplotypes', 'haplotype', 'NNS', 'I-NP', 'O')
('among', 'among', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('calculated', 'calculate', 'VBN', 'I-VP', 'O')
('(Fig.', '(Fig.', 'NNP', 'B-NP', 'O')
1).
('1).', '1).', 'LS', 'B-LST', 'O')
Haplotype block included rs2699895, rs3729679 and rs17849074 among the five polymorphisms.
('Haplotype', 'Haplotype', 'NN', 'B-NP', 'O')
('block', 'block', 'NN', 'I-NP', 'O')
('included', 'include', 'VBD', 'B-VP', 'O')
('rs2699895,', 'rs2699895,', 'NN', 'B-NP', 'O')
('rs3729679', 'rs3729679', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('rs17849074', 'rs17849074', 'NN', 'I-NP', 'O')
('among', 'among', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('five', 'five', 'CD', 'I-NP', 'O')
('polymorphisms.', 'polymorphisms.', 'NNS', 'I-NP', 'O')
Association of lung cancer risk with PIK3CA polymorphisms was then analyzed (Table 2), revealing no association of the five polymorphisms with the risks of   　　　　　　lung cancer.
('Association', 'Association', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'B-protein')
('cancer', 'cancer', 'NN', 'I-NP', 'I-protein')
('risk', 'risk', 'NN', 'I-NP', 'I-protein')
('with', 'with', 'IN', 'B-PP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'B-NP', 'B-DNA')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'I-DNA')
('was', 'be', 'VBD', 'B-VP', 'O')
('then', 'then', 'RB', 'I-VP', 'O')
('analyzed', 'analyze', 'VBN', 'I-VP', 'O')
('(Table', '(Table', 'JJ', 'B-NP', 'B-protein')
('2),', '2),', 'NN', 'I-NP', 'I-protein')
('revealing', 'reveal', 'VBG', 'B-VP', 'O')
('no', 'no', 'DT', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('five', 'five', 'CD', 'I-NP', 'O')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('risks', 'risk', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('\u3000\u3000\u3000\u3000\u3000\u3000lung', '\u3000\u3000\u3000\u3000\u3000\u3000lung', 'NN', 'B-NP', 'O')
('cancer.', 'cancer.', 'NN', 'I-NP', 'O')
The association of the polymorphisms with the risk of lung cancer was further examined after stratifying the subjects according to gender and smoking status.
('The', 'The', 'DT', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'B-DNA')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('risk', 'risk', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('was', 'be', 'VBD', 'B-VP', 'O')
('further', 'further', 'RBR', 'I-VP', 'O')
('examined', 'examine', 'VBN', 'I-VP', 'O')
('after', 'after', 'IN', 'B-PP', 'O')
('stratifying', 'stratify', 'VBG', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('subjects', 'subject', 'NNS', 'I-NP', 'O')
('according', 'accord', 'VBG', 'B-PP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('gender', 'gender', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('smoking', 'smoking', 'NN', 'I-NP', 'O')
('status.', 'status.', 'NNS', 'I-NP', 'O')
However, subsequent analysis also revealed no significant association.
('However,', 'However,', 'WRB', 'B-ADVP', 'O')
('subsequent', 'subsequent', 'JJ', 'B-NP', 'O')
('analysis', 'analysis', 'NN', 'I-NP', 'O')
('also', 'also', 'RB', 'B-ADVP', 'O')
('revealed', 'reveal', 'VBD', 'B-VP', 'O')
('no', 'no', 'DT', 'B-NP', 'O')
('significant', 'significant', 'JJ', 'I-NP', 'O')
('association.', 'association.', 'NN', 'I-NP', 'O')
Furthermore, the haplotypes (CAT, AGT and CAC) of PIK3CA polymorphisms were not associated with the risks of lung cancer in three alternative models (Table 3).
('Furthermore,', 'Furthermore,', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('haplotypes', 'haplotype', 'NNS', 'I-NP', 'O')
('(CAT,', '(CAT,', 'IN', 'B-PP', 'O')
('AGT', 'AGT', 'NN', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('CAC)', 'CAC)', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'B-NP', 'B-DNA')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'I-DNA')
('were', 'be', 'VBD', 'B-VP', 'O')
('not', 'not', 'RB', 'I-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('risks', 'risk', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('three', 'three', 'CD', 'B-NP', 'O')
('alternative', 'alternative', 'JJ', 'I-NP', 'O')
('models', 'model', 'NNS', 'I-NP', 'O')
('(Table', '(Table', 'JJ', 'B-ADJP', 'O')
('3).', '3).', 'CD', 'B-NP', 'O')
Most human malignancies are caused by somatic variations within the cancer genome, leading to activation of oncogenes or inactivation of tumor suppressor genes, and many of the resultant changes target cell signaling pathways (Vogelstein and Kinzler, 2004).
('Most', 'Most', 'JJS', 'B-NP', 'O')
('human', 'human', 'JJ', 'I-NP', 'O')
('malignancies', 'malignancy', 'NNS', 'I-NP', 'O')
('are', 'be', 'VBP', 'B-VP', 'O')
('caused', 'cause', 'VBN', 'I-VP', 'O')
('by', 'by', 'IN', 'B-PP', 'O')
('somatic', 'somatic', 'JJ', 'B-NP', 'O')
('variations', 'variation', 'NNS', 'I-NP', 'O')
('within', 'within', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('genome,', 'genome,', 'NN', 'I-NP', 'O')
('leading', 'lead', 'VBG', 'B-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('activation', 'activation', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('oncogenes', 'oncogene', 'NNS', 'B-NP', 'B-DNA')
('or', 'or', 'CC', 'O', 'O')
('inactivation', 'inactivation', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('tumor', 'tumor', 'NN', 'B-NP', 'B-protein')
('suppressor', 'suppressor', 'NN', 'I-NP', 'I-protein')
('genes,', 'genes,', 'NN', 'I-NP', 'I-protein')
('and', 'and', 'CC', 'O', 'O')
('many', 'many', 'JJ', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('resultant', 'resultant', 'JJ', 'I-NP', 'O')
('changes', 'change', 'NNS', 'I-NP', 'O')
('target', 'target', 'NN', 'I-NP', 'O')
('cell', 'cell', 'NN', 'I-NP', 'O')
('signaling', 'signaling', 'NN', 'I-NP', 'O')
('pathways', 'pathway', 'NNS', 'I-NP', 'O')
('(Vogelstein', '(Vogelstein', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Kinzler,', 'Kinzler,', 'NN', 'B-NP', 'O')
('2004).', '2004).', 'CD', 'I-NP', 'O')
PI3K/AKT pathway is the major pathway controlling cell growth and tumorigenesis (Cantley, 2002; Katso et al., 2001; Vivanco and Sawyers, 2002), and the pathway lies downstream of receptor tyrosine kinase, including EGFR.
('PI3K/AKT', 'PI3K/AKT', 'NN', 'B-NP', 'B-protein')
('pathway', 'pathway', 'NN', 'I-NP', 'O')
('is', 'be', 'VBZ', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('major', 'major', 'JJ', 'I-NP', 'O')
('pathway', 'pathway', 'NN', 'I-NP', 'O')
('controlling', 'control', 'VBG', 'B-VP', 'O')
('cell', 'cell', 'NN', 'B-NP', 'O')
('growth', 'growth', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('tumorigenesis', 'tumorigenesis', 'NN', 'B-NP', 'O')
('(Cantley,', '(Cantley,', 'NNP', 'I-NP', 'O')
('2002;', '2002;', ':', 'O', 'O')
('Katso', 'Katso', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'VBD', 'B-VP', 'O')
('2001;', '2001;', ':', 'O', 'O')
('Vivanco', 'Vivanco', 'NNP', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('Sawyers,', 'Sawyers,', 'NNP', 'I-NP', 'O')
('2002),', '2002),', 'CD', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('pathway', 'pathway', 'NN', 'I-NP', 'O')
('lies', 'lie', 'VBZ', 'B-VP', 'O')
('downstream', 'downstream', 'RB', 'B-ADVP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('receptor', 'receptor', 'NN', 'B-NP', 'O')
('tyrosine', 'tyrosine', 'NN', 'I-NP', 'O')
('kinase,', 'kinase,', 'NN', 'I-NP', 'O')
('including', 'include', 'VBG', 'B-PP', 'O')
('EGFR.', 'EGFR.', 'NNP', 'B-NP', 'O')
In addition to PIK3CA, other components of the pathway, including the loss of the inhibitor PTEN or activating mutation of AKT, occurs in certain cancers (Samuels and Ericson, 2006; Shibata et al., 2009).
('In', 'In', 'IN', 'B-PP', 'O')
('addition', 'addition', 'NN', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('PIK3CA,', 'PIK3CA,', 'NN', 'B-NP', 'B-protein')
('other', 'other', 'JJ', 'I-NP', 'I-protein')
('components', 'component', 'NNS', 'I-NP', 'I-protein')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('pathway,', 'pathway,', 'NN', 'I-NP', 'O')
('including', 'include', 'VBG', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('loss', 'loss', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('inhibitor', 'inhibitor', 'NN', 'I-NP', 'O')
('PTEN', 'PTEN', 'NN', 'I-NP', 'O')
('or', 'or', 'CC', 'O', 'O')
('activating', 'activate', 'VBG', 'B-VP', 'O')
('mutation', 'mutation', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('AKT,', 'AKT,', 'NN', 'B-NP', 'B-protein')
('occurs', 'occur', 'VBZ', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('certain', 'certain', 'JJ', 'B-NP', 'O')
('cancers', 'cancer', 'NNS', 'I-NP', 'O')
('(Samuels', '(Samuel', 'NNPS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('Ericson,', 'Ericson,', 'NNP', 'B-NP', 'O')
('2006;', '2006;', ':', 'O', 'O')
('Shibata', 'Shibata', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2009).', '2009).', 'CD', 'B-NP', 'O')
Recently, a few studies revealed genetic variations of PIK3CA gene in colon, rectal and bladder cancer risk (Chen et al., 2009; Slattery et al., 2010), however, there has been no study done on the association between lung cancer risk and polymorphism of PIK3CA gene in the Korean population.
('Recently,', 'Recently,', 'IN', 'B-PP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('few', 'few', 'JJ', 'I-NP', 'O')
('studies', 'study', 'NNS', 'I-NP', 'O')
('revealed', 'reveal', 'VBD', 'B-VP', 'O')
('genetic', 'genetic', 'JJ', 'B-NP', 'O')
('variations', 'variation', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'B-NP', 'B-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('in', 'in', 'IN', 'B-PP', 'O')
('colon,', 'colon,', 'NN', 'B-NP', 'O')
('rectal', 'rectal', 'JJ', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('bladder', 'bladder', 'NN', 'B-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('risk', 'risk', 'NN', 'I-NP', 'O')
('(Chen', '(Chen', 'NNP', 'I-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'VBD', 'B-VP', 'O')
('2009;', '2009;', ':', 'O', 'B-protein')
('Slattery', 'Slattery', 'NNP', 'B-NP', 'I-protein')
('et', 'et', 'NNP', 'I-NP', 'I-protein')
('al.,', 'al.,', 'NN', 'I-NP', 'I-protein')
('2010),', '2010),', 'VBD', 'B-VP', 'I-protein')
('however,', 'however,', 'NN', 'B-NP', 'I-protein')
('there', 'there', 'EX', 'B-NP', 'O')
('has', 'have', 'VBZ', 'B-VP', 'O')
('been', 'be', 'VBN', 'I-VP', 'O')
('no', 'no', 'DT', 'B-NP', 'O')
('study', 'study', 'NN', 'I-NP', 'O')
('done', 'do', 'VBN', 'B-VP', 'O')
('on', 'on', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'B-protein')
('cancer', 'cancer', 'NN', 'I-NP', 'I-protein')
('risk', 'risk', 'NN', 'I-NP', 'I-protein')
('and', 'and', 'CC', 'O', 'O')
('polymorphism', 'polymorphism', 'NN', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'B-NP', 'B-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Korean', 'Korean', 'JJ', 'I-NP', 'O')
('population.', 'population.', 'NN', 'I-NP', 'O')
In this study, we hypothesized that PIK3CA polymorphisms are associated with lung cancer risk.
('In', 'In', 'IN', 'B-PP', 'O')
('this', 'this', 'DT', 'B-NP', 'O')
('study,', 'study,', 'NN', 'I-NP', 'O')
('we', 'we', 'PRP', 'B-NP', 'O')
('hypothesized', 'hypothesize', 'VBD', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'B-NP', 'B-DNA')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'I-DNA')
('are', 'be', 'VBP', 'B-VP', 'O')
('associated', 'associate', 'VBN', 'I-VP', 'O')
('with', 'with', 'IN', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('risk.', 'risk.', 'NN', 'I-NP', 'O')
However, our finding indicated no association between PIK3CA polymorphisms and lung cancer risk in the Korean population.
('However,', 'However,', 'WRB', 'B-ADVP', 'O')
('our', 'our', 'PRP$', 'B-NP', 'O')
('finding', 'finding', 'NN', 'I-NP', 'O')
('indicated', 'indicate', 'VBD', 'B-VP', 'O')
('no', 'no', 'DT', 'B-NP', 'O')
('association', 'association', 'NN', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'B-NP', 'B-DNA')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'I-DNA')
('and', 'and', 'CC', 'O', 'O')
('lung', 'lung', 'NN', 'B-NP', 'B-protein')
('cancer', 'cancer', 'NN', 'I-NP', 'I-protein')
('risk', 'risk', 'NN', 'I-NP', 'I-protein')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('Korean', 'Korean', 'JJ', 'I-NP', 'O')
('population.', 'population.', 'NN', 'I-NP', 'O')
Genetic variations often show ethnic variation (Kim et al., 2006; Kim et al., 2008).
('Genetic', 'Genetic', 'JJ', 'B-NP', 'O')
('variations', 'variation', 'NNS', 'I-NP', 'O')
('often', 'often', 'RB', 'B-ADVP', 'O')
('show', 'show', 'VBP', 'B-VP', 'O')
('ethnic', 'ethnic', 'JJ', 'B-NP', 'B-cell_type')
('variation', 'variation', 'NN', 'I-NP', 'I-cell_type')
('(Kim', '(Kim', 'NNP', 'I-NP', 'I-cell_type')
('et', 'et', 'NNP', 'I-NP', 'I-cell_type')
('al.,', 'al.,', 'VBD', 'B-VP', 'I-cell_type')
('2006;', '2006;', ':', 'O', 'I-cell_type')
('Kim', 'Kim', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2008).', '2008).', 'CD', 'B-NP', 'O')
In the present study, the observed frequencies of the minor alleles of rs11709323, rs2699895, rs3729679, rs17849074 and rs1356413 were 0.116, 0.186, 0.189, 0.041 and 0.111, respectively.
('In', 'In', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('present', 'present', 'JJ', 'I-NP', 'O')
('study,', 'study,', 'NN', 'I-NP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('observed', 'observe', 'VBN', 'I-NP', 'O')
('frequencies', 'frequency', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('minor', 'minor', 'JJ', 'I-NP', 'O')
('alleles', 'allele', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('rs11709323,', 'rs11709323,', 'NN', 'B-NP', 'O')
('rs2699895,', 'rs2699895,', 'NN', 'I-NP', 'O')
('rs3729679,', 'rs3729679,', 'NN', 'I-NP', 'O')
('rs17849074', 'rs17849074', 'NN', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('rs1356413', 'rs1356413', 'NN', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('0.116,', '0.116,', 'CD', 'B-NP', 'O')
('0.186,', '0.186,', 'CD', 'I-NP', 'O')
('0.189,', '0.189,', 'CD', 'I-NP', 'O')
('0.041', '0.041', 'CD', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('0.111,', '0.111,', 'CD', 'I-NP', 'O')
('respectively.', 'respectively.', 'NN', 'I-NP', 'O')
According to the HapMap database, the frequencies of the minor alleles in Asian ethnic groups (Han Chinese and Japanese) were shown to be 0.045, 0.148, 0.193, 0.045 and 0.039, respectively, thus showing similar frequencies to the present study.
('According', 'Accord', 'VBG', 'B-PP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('HapMap', 'HapMap', 'NNP', 'I-NP', 'O')
('database,', 'database,', 'VBD', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('frequencies', 'frequency', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('minor', 'minor', 'JJ', 'I-NP', 'B-DNA')
('alleles', 'allele', 'NNS', 'I-NP', 'I-DNA')
('in', 'in', 'IN', 'B-PP', 'O')
('Asian', 'Asian', 'JJ', 'B-NP', 'O')
('ethnic', 'ethnic', 'JJ', 'I-NP', 'O')
('groups', 'group', 'NNS', 'I-NP', 'O')
('(Han', '(Han', 'VBP', 'B-VP', 'O')
('Chinese', 'Chinese', 'JJ', 'B-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('Japanese)', 'Japanese)', 'NNP', 'I-NP', 'O')
('were', 'be', 'VBD', 'B-VP', 'O')
('shown', 'show', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'I-VP', 'O')
('be', 'be', 'VB', 'I-VP', 'O')
('0.045,', '0.045,', 'CD', 'B-NP', 'O')
('0.148,', '0.148,', 'CD', 'I-NP', 'O')
('0.193,', '0.193,', 'CD', 'I-NP', 'O')
('0.045', '0.045', 'CD', 'I-NP', 'O')
('and', 'and', 'CC', 'I-NP', 'O')
('0.039,', '0.039,', 'CD', 'I-NP', 'O')
('respectively,', 'respectively,', 'NN', 'I-NP', 'O')
('thus', 'thus', 'RB', 'B-ADVP', 'O')
('showing', 'show', 'VBG', 'B-VP', 'O')
('similar', 'similar', 'JJ', 'B-NP', 'O')
('frequencies', 'frequency', 'NNS', 'I-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('present', 'present', 'JJ', 'I-NP', 'O')
('study.', 'study.', 'NN', 'I-NP', 'O')
A series of our previous studies showed that polymorphisms of oncogene, tumor suppressor gene and receptor tyrosine kinase are related to lung cancer risk (Choi et al., 2009; Jo et al., 2008; Kim et al., 2010; Sung et al., 2008).
('A', 'A', 'DT', 'B-NP', 'O')
('series', 'series', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('our', 'our', 'PRP$', 'B-NP', 'O')
('previous', 'previous', 'JJ', 'I-NP', 'O')
('studies', 'study', 'NNS', 'I-NP', 'O')
('showed', 'show', 'VBD', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('polymorphisms', 'polymorphism', 'NNS', 'B-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('oncogene,', 'oncogene,', 'NN', 'B-NP', 'B-DNA')
('tumor', 'tumor', 'NN', 'I-NP', 'I-DNA')
('suppressor', 'suppressor', 'NN', 'I-NP', 'I-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('and', 'and', 'CC', 'O', 'O')
('receptor', 'receptor', 'NN', 'B-NP', 'B-protein')
('tyrosine', 'tyrosine', 'NN', 'I-NP', 'I-protein')
('kinase', 'kinase', 'NN', 'I-NP', 'I-protein')
('are', 'be', 'VBP', 'B-VP', 'O')
('related', 'relate', 'VBN', 'I-VP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'B-protein')
('cancer', 'cancer', 'NN', 'I-NP', 'I-protein')
('risk', 'risk', 'NN', 'I-NP', 'I-protein')
('(Choi', '(Choi', 'NNP', 'I-NP', 'I-protein')
('et', 'et', 'NNP', 'I-NP', 'I-protein')
('al.,', 'al.,', 'VBD', 'B-VP', 'I-protein')
('2009;', '2009;', ':', 'O', 'I-protein')
('Jo', 'Jo', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al.,', 'al.,', 'FW', 'I-NP', 'O')
('2008;', '2008;', ':', 'O', 'O')
('Kim', 'Kim', 'NNP', 'B-NP', 'O')
('et', 'et', 'FW', 'I-NP', 'O')
('al.,', 'al.,', 'FW', 'I-NP', 'O')
('2010;', '2010;', ':', 'O', 'O')
('Sung', 'Sung', 'NNP', 'B-NP', 'O')
('et', 'et', 'NNP', 'I-NP', 'O')
('al.,', 'al.,', 'IN', 'B-PP', 'O')
('2008).', '2008).', 'CD', 'B-NP', 'O')
On the other hand, however, the genotypes of PIK3CA gene polymorphisms, determined in 866 Koreans in the present study, revealed no significant difference between lung cancer patients and normal controls.
('On', 'On', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('other', 'other', 'JJ', 'I-NP', 'O')
('hand,', 'hand,', 'NN', 'I-NP', 'O')
('however,', 'however,', 'VBD', 'B-VP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('genotypes', 'genotype', 'NNS', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'B-NP', 'B-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('polymorphisms,', 'polymorphisms,', 'NN', 'I-NP', 'O')
('determined', 'determine', 'VBN', 'B-VP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('866', '866', 'CD', 'B-NP', 'O')
('Koreans', 'Korean', 'NNPS', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('present', 'present', 'JJ', 'I-NP', 'O')
('study,', 'study,', 'NN', 'I-NP', 'O')
('revealed', 'reveal', 'VBD', 'B-VP', 'O')
('no', 'no', 'DT', 'B-NP', 'O')
('significant', 'significant', 'JJ', 'I-NP', 'O')
('difference', 'difference', 'NN', 'I-NP', 'O')
('between', 'between', 'IN', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'O')
('cancer', 'cancer', 'NN', 'I-NP', 'O')
('patients', 'patient', 'NNS', 'I-NP', 'O')
('and', 'and', 'CC', 'O', 'O')
('normal', 'normal', 'JJ', 'B-NP', 'O')
('controls.', 'controls.', 'NNS', 'I-NP', 'O')
This result suggests that PIK3CA gene polymorphisms are not likely to play a major role in the susceptibility of Korean to lung cancer.
('This', 'This', 'DT', 'B-NP', 'O')
('result', 'result', 'NN', 'I-NP', 'O')
('suggests', 'suggest', 'VBZ', 'B-VP', 'O')
('that', 'that', 'IN', 'B-SBAR', 'O')
('PIK3CA', 'PIK3CA', 'NN', 'B-NP', 'B-DNA')
('gene', 'gene', 'NN', 'I-NP', 'I-DNA')
('polymorphisms', 'polymorphism', 'NNS', 'I-NP', 'I-DNA')
('are', 'be', 'VBP', 'B-VP', 'O')
('not', 'not', 'RB', 'O', 'O')
('likely', 'likely', 'JJ', 'B-ADJP', 'O')
('to', 'to', 'TO', 'B-VP', 'O')
('play', 'play', 'VB', 'I-VP', 'O')
('a', 'a', 'DT', 'B-NP', 'O')
('major', 'major', 'JJ', 'I-NP', 'O')
('role', 'role', 'NN', 'I-NP', 'O')
('in', 'in', 'IN', 'B-PP', 'O')
('the', 'the', 'DT', 'B-NP', 'O')
('susceptibility', 'susceptibility', 'NN', 'I-NP', 'O')
('of', 'of', 'IN', 'B-PP', 'O')
('Korean', 'Korean', 'JJ', 'B-NP', 'O')
('to', 'to', 'TO', 'B-PP', 'O')
('lung', 'lung', 'NN', 'B-NP', 'O')
('cancer.', 'cancer.', 'NN', 'I-NP', 'O')
